On September 6, 2022 Celularity Inc. (Nasdaq: CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, reported that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will participate in fireside chats at the following investor conferences (Press release, Celularity, SEP 6, 2022, View Source;utm_medium=rss&utm_campaign=celularity-announces-participation-in-upcoming-investor-conferences [SID1234619119]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 1:30 p.m. ET
Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022, at 12:20 p.m. ET
A live webcast of the fireside chats can be accessed on the Investors section of Celularity’s website at View Source A replay of the webcasts will be archived and available following the event for approximately 30 days.